Roivant’s Mosliciguat Shines in Phase 2, Sending ROIV Shares Toward All‑Time High

Roivant Sciences (ROIV) lit up the market on Tuesday when its experimental lung‑disease drug Mosliciguat hit the primary endpoint in a pivotal Phase 2 study. The news, surprising to some but welcomed by many investors, pushed the stock up roughly 22% in pre‑market trading, edging it toward a fresh record high.

The Phase 2 trial, dubbed PHocus, enrolled 135 patients suffering from pulmonary hypertension linked to interstitial lung disease (PH‑ILD). After 16 weeks, participants receiving Mosliciguat saw pulmonary vascular resistance—a measure of how hard the heart has to work to push blood through the lungs—drop by an impressive 56.3% versus placebo. In plain English, the heart faced far less strain.

But the numbers weren’t just about pressure. In the classic 6‑Minute Walk Distance test, those on Mosliciguat walked an extra 35.2 metres compared with the control group, a modest yet meaningful gain for people whose daily activity is often limited. The drug also trimmed NT‑proBNP, a heart‑stress marker, by about 53%, underscoring its broader cardiac benefits.

Encouraged by these results, Roivant has already kicked off enrollment for a larger Phase 3 trial, named PHrontier. The company estimates that PH‑ILD affects up to 200,000 individuals across the U.S. and Europe—a patient pool comparable in size to many oncology indications. “PH‑ILD is as deadly as some cancers, with median survival of just 1.5‑2 years despite standard care,” explained Mayukh Sukhatme, Roivant’s President and CIO, adding that Mosliciguat’s data puts it “in a league of its own.”

Investor sentiment mirrored the clinical optimism. On Stocktwits, the tone swung from bearish to bullish in the past day, and the stock has already logged a near‑doubling in value this year. While some traders still flag short‑selling opportunities, the prevailing mood is upbeat, driven by the drug’s clear efficacy signals and the looming Phase 3 launch.

For anyone tracking biotech upside, Mosliciguat’s story is a reminder that solid trial data can still spark rapid market moves, especially when a disease area remains underserved. As the Phase 3 trial unfolds, all eyes will be on Roivant to see whether the early promise translates into a full‑blown therapeutic breakthrough.